Shield Therapeutics (STX); positive results from long-term phase of AEGIS-CKD study

Published on 29-01-2019 08:25:32
Author Sparks Team
Glaxosmithkline (GSK); AB generic approved as substitute for Advair

Shield Therapeutics has announced positive results from the open-label extension phase of the AEGIS-CKD pivotal study of Feraccru. The new drug is a novel oral ferric iron therapy used in the European Union for the treatment of iron deficiency (ID) in adults and in Switzerland, for the treatment of IDA in adults with inflammatory bowel disease (IBD).

Carl Sterritt, Shield Therapeutic’s CEO and Founder, said: “Such positive long-term treatment data for Feraccru® in complex patients with chronic diseases like CKD provides a very promising signal for the future commercial success of Feraccru®. Having previously seen similar positive long-term effects in IBD patients with IDA this further clinical trial data provides additional evidence that Feraccru is well-tolerated by a majority of treated patients and is effective at correcting IDA.”

Share this with friends and colleagues

Company list